Investor / Analyst Event Update

RNS Number : 2692F

Advanced Oncotherapy PLC

03 November 2022

 

REACH: non-regulatory announcement

3 November 2022

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Investor / Analyst Event Update

Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation proton therapy system for cancer treatment, announces that due to the high number of requests to attend the event, as well as the impact of the rail strikes planned next week affecting travel to/ from the Company's assembly site at Daresbury on Tuesday, 8 November, the Company is scheduling an additional investor/ analyst event on Tuesday, 22 November for those not able to attend the one scheduled next week.

To register your interest in attending this additional event on Tuesday, 22 November, or the event on Tuesday, 8 November, please contact [e-mail] . The events will be held in person and will also include a tour of the site's technical area including the first operational LIGHT system. Due to health and safety restrictions in the technical area of the LIGHT system the total number of visitors is limited and therefore any application to attend the event will be subsequently confirmed based on the total number of registrations received.

The presentation will be available on the Company's website on 8 November 2022, the day of the first event.

For more information on LIGHT, please see this video explaining the technology.

The full agenda for both events is as follows:

Presentation	Time (GMT)
Arrival at Daresbury	12:45
Presentation by the Company's management including:	13:00 - 14:00
Nicolas Serandour, Chief Executive Officer
Prof. Steve Myers. Executive Chairman ADAM S.A.
Ed Lee, Chief Operating Officer
Moataz Karmalawy, Chief Commercial Officer
Jonathan Farr, Chief Clinical Officer
Tour of the technical area and LIGHT system	14:00 - 15:30
Q&A	15:30 - 16:30

- ENDS -

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

Notes to Editors

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

END

 

 

NRAUOAVRUOUARAA